Shares of Mirum Pharmaceuticals, Inc. (MIRM) have rallied 31.5% in the past three months against the industry’s decrease of 1.5%.Last month, the company submitted a new drug application (NDA) seeking approval for chenodiol for treating cerebrotendinous xanthomatosis (CTX) patients in the United States. The NDA filing was based on positive data from the phase III RESTORE study.Data from the study showed that treatment with chenodiol significantly improved serum cholestanol. The RESTORE study met its primary ...